Meet the NeuroArbor team

Scientific commitment and patient-centric clinical expertise are the pillars of our work. Our team collaborates with leading universities and experts in the field of liver and metabolic disorders, neurology and psychiatry.

Our scientists and clinicians have worked in top medical institutions, including, among others, Harvard University, Cornell University, the University of Texas, Johns Hopkins University,The University of Padova, The University of Milano, The Swiss Italian University (USI), Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, Massachusetts General Hospital.

Paolo Manfredi

Chief Scientific Officer and Chief Executive Officer

Paolo Manfredi is a neurologist and co-founder of Medeor Inc. a joint venture with Cornell Center for Technology Enterprise & Commercialization (CCTEC). Medeor then merged to form Relmada Therapeutics, a publicly traded biotechnology company. Dr. Manfredi is a co-inventor of several pharmaceutical patents currently under development. REL-P11 (MR psilocybin) has successfully completed a Phase 1 study in overweight-obese subjects and in normal BMI subjects and is preparing for Phase 2 studies. REL-1017 (esmethadone), a well tolerated and safe oral, once-daily NMDA receptor antagonist is currently in Phase 3 for the adjunctive treatment of major depressive disorder by Levomecor Inc.

Marco Pappagallo

Chief Medical Officer and Head of Safety

Marco Pappagallo is a Neurologist and Clinical Professor of Anesthesiology at Albert Einstein College of Medicine, New York. Marco is an internationally renowned researcher and lecturer with over 100 publications and a seasoned inventor of pharmaceuticals. Marco has conducted (PI) clinical trials sponsored by NIH, Glaxo, Roche, and Pfizer and has held CMO positions in several biotechnology companies, including Relmada Therapeutics. Marco is a co-inventor on the psilocybin platform, which includes REL-P11, a Phase 2-ready molecule.

Marco Massini

Chief Financial Officer

Marco Massini is an investor, board director, and operating CFO with deep experience in financial strategy, M&A, and value creation for private-equity-backed companies. He has supported the growth and financial governance of 15+ portfolio companies across consumer, industrial, and technology sectors. His expertise spans enterprise valuation, budgeting and forecasting, cash-flow optimization, debt and equity structuring, turn-around support and board-level reporting, with a strong focus on cross-border operations between the U.S. and Europe. Marco holds an MBA from Columbia Business School and a B.S. in Mechanical Engineering from the University of Parma.